Clinical Trial Update: Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

View source ↗

Summary

This clinical trial update reports on treatment with second-generation tyrosine kinase inhibitors after imatinib failure in chronic-phase chronic myeloid leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myeloid, Chronic-Phase (CML-CP) | Status: COMPLETED